TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants
Brief Summary: The research team is comprised of an expert nutrition scientist and a pediatrician with expertise in endocrinology. Both have world-class experience in assessing bone mass in infancy. Together they have designed a study to determine how much dietary vitamin D is needed to optimize health in infants. This is important since many infants are born with vitamin D deficiency. At present the dosage of vitamin D that is optimal for infant health is unclear and recent research suggests that vitamin D status very early in life has long lasting effects on bone mass and other health issues. Therefore, in a group of healthy infants, this research team will test which dosage of vitamin D is needed to achieve optimal vitamin D status. Optimal vitamin D status will be based on growth, biomarkers of vitamin D and bone status in blood and also general health. The infants will all be breastfed and begin the study at about 2 weeks of age. At 3 months intervals over the first year of life, each infant will be measured for growth, duration of breastfeeding and supplement use plus have a bone density scan to determine changes in bone growth. The data will be helpful to guide health care professionals in providing the best care possible for their infants. It will also be important to the health of populations since dietary recommendations for vitamin D are used to guide fortification of foods and development of evidence based policy around nutrient recommendations and their implementation.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Vitamin D3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin D | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants
Brief Summary: The research team is comprised of an expert nutrition scientist and a pediatrician with expertise in endocrinology. Both have world-class experience in assessing bone mass in infancy. Together they have designed a study to determine how much dietary vitamin D is needed to optimize health in infants. This is important since many infants are born with vitamin D deficiency. At present the dosage of vitamin D that is optimal for infant health is unclear and recent research suggests that vitamin D status very early in life has long lasting effects on bone mass and other health issues. Therefore, in a group of healthy infants, this research team will test which dosage of vitamin D is needed to achieve optimal vitamin D status. Optimal vitamin D status will be based on growth, biomarkers of vitamin D and bone status in blood and also general health. The infants will all be breastfed and begin the study at about 2 weeks of age. At 3 months intervals over the first year of life, each infant will be measured for growth, duration of breastfeeding and supplement use plus have a bone density scan to determine changes in bone growth. The data will be helpful to guide health care professionals in providing the best care possible for their infants. It will also be important to the health of populations since dietary recommendations for vitamin D are used to guide fortification of foods and development of evidence based policy around nutrient recommendations and their implementation.


Options:
A: Arm Label: Arm A; Type: N/A; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: Arm B; Type: N/A; Interventions: Dietary Supplement: 2000 IU vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): Arm A | Intervention Type: DIETARY_SUPPLEMENT; Name: 2000 IU vitamin D3; Assigned to Arm(s): Arm B
B: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Placebo, Vitamin D
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: 400 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: 4000 IU vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): 400 IU vitamin D, 4000 IU vitamin D

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux.
Brief Summary: The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with vesico-ureteral reflux (VUR).


Options:
A: Intervention Type: DRUG; Name: antibiotic to reduce the recurrence of infection; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: oral amoxicilline/clavulanic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iv ceftriaxone; Assigned to Arm(s): N/A
C: Arm Label: Trimethoprim-Sulfamethoxazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-Sulfamethoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trimethoprim-Sulfamethoxazole; Assigned to Arm(s): Trimethoprim-Sulfamethoxazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: sulfamethoxazole/trimethoprim; Type: EXPERIMENTAL; Interventions: Drug: Sulfamethoxazole/trimethoprim | Arm Label: No prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfamethoxazole/trimethoprim; Assigned to Arm(s): sulfamethoxazole/trimethoprim

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Antibiotic Prophylaxis After Acute Pyelonephritis for Prevention of Urinary Tract Infections in Children With Vesico-Ureteral Reflux.
Brief Summary: The aim of this study is to assess the effectiveness of antibiotic prophylaxis in preventing pyelonephritis and in avoiding the appearance of new scars in a sample of children under 36 months with vesico-ureteral reflux (VUR).


Options:
A: Arm Label: sulfamethoxazole/trimethoprim; Type: EXPERIMENTAL; Interventions: Drug: Sulfamethoxazole/trimethoprim | Arm Label: No prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfamethoxazole/trimethoprim; Assigned to Arm(s): sulfamethoxazole/trimethoprim
B: Arm Label: Trimethoprim-Sulfamethoxazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-Sulfamethoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trimethoprim-Sulfamethoxazole; Assigned to Arm(s): Trimethoprim-Sulfamethoxazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: oral amoxicilline/clavulanic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iv ceftriaxone; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: antibiotic to reduce the recurrence of infection; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Studying the Effects of Phosphatidylserine Enriched With Omega-3 Fatty Acids on Symptoms of Attention-Deficit/Hyperactivity Disorder in Children
Brief Summary: To determine whether supplementation of omega-3 long-chain polyunsaturated fatty acid conjugated to phosphatidylserine rather than triglycerides (fish oil) could affect Attention-deficit/hyperactivity disorder symptoms in children.


Options:
A: Arm Label: Wheat germ oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Wheat germ oil | Arm Label: docosahexaenoic acid; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: docosahexaenoic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: docosahexaenoic acid; Assigned to Arm(s): docosahexaenoic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat germ oil; Assigned to Arm(s): Wheat germ oil
B: Intervention Type: DRUG; Name: Phosphatidylserine-Omega3; Assigned to Arm(s): N/A
C: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Omega 3/6 fatty acids | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega 3/6 fatty acids; Assigned to Arm(s): Active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ADHD active; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Eicosapentaenoic acid / Docosahexaenoic acid | Arm Label: ADHD Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo dietary intervention (MUFA) in ADHD group | Arm Label: Active Healthy control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Eicosapentaenoic acid / Docosahexaenoic acid | Arm Label: Healthy placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo dietary intervention (MUFA) in healthy control group | Intervention Type: DIETARY_SUPPLEMENT; Name: Eicosapentaenoic acid / Docosahexaenoic acid; Assigned to Arm(s): ADHD active | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo dietary intervention (MUFA) in ADHD group; Assigned to Arm(s): ADHD Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Eicosapentaenoic acid / Docosahexaenoic acid; Assigned to Arm(s): Active Healthy control | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo dietary intervention (MUFA) in healthy control group; Assigned to Arm(s): Healthy placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-dose Primary Vaccination.
Brief Summary: The aim of this this study is to evaluate the lot-to-lot consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate the liquid formulation compared to the lyophilised formulation of GSK Biologicals' HRV vaccine when administered concomitantly with a combination childhood vaccine.


Options:
A: Arm Label: PLACEBO-ROTARIX-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: ROTARIX-PLACEBO-ROTARIX GROUP; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: PLACEBO GROUP; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): PLACEBO GROUP, PLACEBO-ROTARIX-ROTARIX GROUP, ROTARIX-PLACEBO-ROTARIX GROUP
B: Arm Label: Rotarix + No IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: Rotarix | Arm Label: Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine), Biological: Rotarix | Arm Label: No Rotarix + No IPV (inactivated polio vaccine); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: No Rotarix + IPV (inactivated polio vaccine); Type: EXPERIMENTAL; Interventions: Biological: IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: IPV (inactivated polio vaccine); Assigned to Arm(s): No Rotarix + IPV (inactivated polio vaccine), Rotarix + IPV (inactivated polio vaccine) | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix + IPV (inactivated polio vaccine), Rotarix + No IPV (inactivated polio vaccine)
C: Intervention Type: BIOLOGICAL; Name: Live attenuated human rotavirus vaccine; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-dose Primary Vaccination.
Brief Summary: The aim of this this study is to evaluate the lot-to-lot consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate the liquid formulation compared to the lyophilised formulation of GSK Biologicals' HRV vaccine when administered concomitantly with a combination childhood vaccine.


Options:
A: Arm Label: Liq_A Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Liq_B Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Liq_C Group; Type: EXPERIMENTAL; Interventions: Biological: HRV PCV-free liquid vaccine | Arm Label: Lyo Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix | Intervention Type: BIOLOGICAL; Name: HRV PCV-free liquid vaccine; Assigned to Arm(s): Liq_A Group, Liq_B Group, Liq_C Group | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Lyo Group
B: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: Rotavirus (vaccine); Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study to Evaluate Clinical Consistency of the Liquid Formulation of GSK Biologicals' HRV Vaccine and to Evaluate Liquid Formulation Compared to Lyophilised Formulation of the HRV Vaccine Administered as a Two-dose Primary Vaccination.
Brief Summary: The aim of this this study is to evaluate the lot-to-lot consistency of the liquid formulation of GSK Biologicals' HRV vaccine and to evaluate the liquid formulation compared to the lyophilised formulation of GSK Biologicals' HRV vaccine when administered concomitantly with a combination childhood vaccine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: Rotateq™ | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Intervention Type: BIOLOGICAL; Name: Rotateq™; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2
B: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
C: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
D: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial
Brief Summary: The purpose of this study is to determine if patients in the HeartNet Ventricular Support System with optimal medical and device therapy arm (Treatment group) show statistically significant improvement compared to patients in the optimal medical and device therapy alone arm (Control group) after 6 months of follow-up.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: HeartNet Ventricular Support System | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal Medical/Device Therapy | Intervention Type: DEVICE; Name: HeartNet Ventricular Support System; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Optimal Medical/Device Therapy; Assigned to Arm(s): Control
B: Arm Label: Immediate multivessel PCI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Immediate multivessel PCI | Arm Label: Culprit lesion only PCI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Culprit Lesion only PCI | Intervention Type: PROCEDURE; Name: Immediate multivessel PCI; Assigned to Arm(s): Immediate multivessel PCI | Intervention Type: PROCEDURE; Name: Culprit Lesion only PCI; Assigned to Arm(s): Culprit lesion only PCI
C: Arm Label: CCPR protocol; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ECPR protocol; Type: EXPERIMENTAL; Interventions: Procedure: Extracorporeal cardiopulmonary resuscitation (ECPR) | Intervention Type: PROCEDURE; Name: Extracorporeal cardiopulmonary resuscitation (ECPR); Assigned to Arm(s): ECPR protocol
D: Arm Label: Control arm of study; Type: NO_INTERVENTION; Interventions: Device: Counterpulsation with IAB | Intervention Type: DEVICE; Name: Counterpulsation with IAB; Assigned to Arm(s): Control arm of study

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.
Brief Summary: The aim of this study is to reveal that inhaled corticosteroid therapy combined with a short-acting beta2- agonist given on a symptom driven basis is as effective as traditional asthma therapy.

Thus, three advantages will be achieved:

1. better compliance with treatment since patients will most likely have to administer the treatment less frequently,
2. maximum pharmacological effect with the least amount of drug and
3. less economic burden on health care providers.


Options:
A: Intervention Type: DRUG; Name: Pulmicort (budesonide) pMDI; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days); Assigned to Arm(s): N/A
C: Arm Label: Placebo Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Arm Label: Budesonide; Type: EXPERIMENTAL; Interventions: Drug: Budesonide, Drug: Placebo Budesonide | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide | Intervention Type: DRUG; Name: Placebo Budesonide; Assigned to Arm(s): Budesonide, Placebo Budesonide
D: Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multinational, Double Blind, Randomised, Parallel Group Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate 250 mg Combined With Salbutamol 100 mg in the Treatment of Patients With Mild Persistent Asthma.
Brief Summary: The aim of this study is to reveal that inhaled corticosteroid therapy combined with a short-acting beta2- agonist given on a symptom driven basis is as effective as traditional asthma therapy.

Thus, three advantages will be achieved:

1. better compliance with treatment since patients will most likely have to administer the treatment less frequently,
2. maximum pharmacological effect with the least amount of drug and
3. less economic burden on health care providers.


Options:
A: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
B: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
C: Arm Label: Symptom-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Symptom-based adjustment | Arm Label: Biomarker-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Biomarker-based adjustment | Arm Label: Guideline-based adjustment; Type: EXPERIMENTAL; Interventions: Behavioral: Guideline-based adjustment | Intervention Type: BEHAVIORAL; Name: Symptom-based adjustment; Assigned to Arm(s): Symptom-based adjustment | Intervention Type: BEHAVIORAL; Name: Biomarker-based adjustment; Assigned to Arm(s): Biomarker-based adjustment | Intervention Type: BEHAVIORAL; Name: Guideline-based adjustment; Assigned to Arm(s): Guideline-based adjustment
D: Intervention Type: DRUG; Name: beclomethasone/salbutamol combination; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beclomethasone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: salbutamol; Assigned to Arm(s): N/A

Answer: D